0001209191-19-004550.txt : 20190118 0001209191-19-004550.hdr.sgml : 20190118 20190118161509 ACCESSION NUMBER: 0001209191-19-004550 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190116 FILED AS OF DATE: 20190118 DATE AS OF CHANGE: 20190118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Danziger Asaf CENTRAL INDEX KEY: 0001654435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 19533398 MAIL ADDRESS: STREET 1: 5 NACHUM CHAT ST. CITY: TIRAT HACARMEL STATE: L3 ZIP: 5112302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-16 0 0001645113 NovoCure Ltd NVCR 0001654435 Danziger Asaf C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 1 1 0 0 Chief Executive Officer Ordinary Shares 2019-01-16 4 M 0 100000 3.44 A 271164 D Ordinary Shares 2019-01-16 4 S 0 98213 45.049 D 172951 D Ordinary Shares 2019-01-16 4 S 0 1787 45.275 D 171164 D Ordinary Shares 2019-01-17 4 M 0 100000 3.44 A 271164 D Ordinary Shares 2019-01-17 4 S 0 100000 45.264 D 171164 D Options to Buy Ordinary Shares 3.44 2019-01-16 4 M 0 100000 0.00 D 2021-12-13 Ordinary Shares 100000 146863 D Options to Buy Ordinary Shares 3.44 2019-01-17 4 M 0 100000 0.00 D 2021-12-13 Ordinary Shares 100000 46863 D These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 98,213 shares in multiple trades at prices ranging from $44.25 to $45.24. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,787 shares in multiple trades at prices ranging from $45.25 to $45.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. On January 17, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $44.90 to $45.55. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Fully vested and currently exercisable as of the date hereof. By: /s/ Kimberly Burke, Attorney in fact for Asaf Danziger 2019-01-18